Biostage Stock Current Valuation
| BSTGDelisted Stock | USD 4.20 0.09 2.10% |
Valuation analysis of Biostage helps investors to measure Biostage's intrinsic value by examining its available valuation indicators, including the cash flow records, the balance sheet account changes and income statement patterns.
Overvalued
Today
Please note that Biostage's price fluctuation is very steady at this time. Calculation of the real value of Biostage is based on 3 months time horizon. Increasing Biostage's time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
The fair value of the Biostage otc stock is determined by what a typical buyer is willing to pay for full or partial control of Biostage. Since Biostage is currently traded on the exchange, buyers and sellers on that exchange determine the market value of Biostage OTC Stock. However, Biostage's intrinsic value may or may not be the same as its current market price, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value. | Historical | Market 4.2 | Real 3.86 | Hype 4.2 | Naive 4.33 |
The real value of Biostage OTC Stock, also known as its intrinsic value, is the underlying worth of Biostage OTC Stock, which is reflected in its stock price. It is based on Biostage's financial performance, growth prospects, management team, or industry conditions. The intrinsic value of Biostage's stock can be calculated using various methods such as discounted cash flow analysis, price-to-earnings ratio, or price-to-book ratio. That value may differ from its current market price, which is determined by supply and demand factors such as investor sentiment, market trends, or news.
Estimating the potential upside or downside of Biostage helps investors to forecast how Biostage otc stock's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of Biostage more accurately as focusing exclusively on Biostage's fundamentals will not take into account other important factors: Biostage OTC Stock Current Valuation Analysis
Biostage's Enterprise Value is a firm valuation proxy that approximates the current market value of a company. It is typically used to determine the takeover or merger price of a firm. Unlike Market Cap, this measure takes into account the entire liquid asset, outstanding debt, and exotic equity instruments that the company has on its balance sheet. When a takeover occurs, the parent company will have to assume the target company's liabilities but will take possession of all cash and cash equivalents.
Current Biostage Current Valuation | 78.64 M |
Most of Biostage's fundamental indicators, such as Current Valuation, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Biostage is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Enterprise Value can be a useful tool to compare companies with different capital structures. Long term liability and current cash or cash equivalents can have a huge impact on market valuation of a given company.
CompetitionIn accordance with the recently published financial statements, Biostage has a Current Valuation of 78.64 M. This is 99.45% lower than that of the Biotechnology sector and 98.31% lower than that of the Health Care industry. The current valuation for all United States stocks is 99.53% higher than that of the company.
Biostage Current Valuation Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Biostage's direct or indirect competition against its Current Valuation to detect undervalued stocks with similar characteristics or determine the otc stocks which would be a good addition to a portfolio. Peer analysis of Biostage could also be used in its relative valuation, which is a method of valuing Biostage by comparing valuation metrics of similar companies.Biostage is currently under evaluation in current valuation category among its peers.
Biostage Fundamentals
| Return On Equity | -4.92 | |||
| Return On Asset | -2.11 | |||
| Current Valuation | 78.64 M | |||
| Shares Outstanding | 11.64 M | |||
| Shares Owned By Insiders | 50.95 % | |||
| Number Of Shares Shorted | 121.66 K | |||
| Price To Earning | (0.16) X | |||
| Price To Book | 28.47 X | |||
| EBITDA | (8.36 M) | |||
| Net Income | (7.98 M) | |||
| Cash And Equivalents | 4.64 M | |||
| Cash Per Share | 0.40 X | |||
| Total Debt | 115 K | |||
| Debt To Equity | 0.04 % | |||
| Current Ratio | 2.26 X | |||
| Book Value Per Share | (0.16) X | |||
| Cash Flow From Operations | (2.63 M) | |||
| Short Ratio | 3.35 X | |||
| Earnings Per Share | (0.89) X | |||
| Target Price | 3.0 | |||
| Beta | -0.91 | |||
| Market Capitalization | 73.82 M | |||
| Total Asset | 1.87 M | |||
| Retained Earnings | (65.78 M) | |||
| Working Capital | 7.23 M | |||
| Current Asset | 7.88 M | |||
| Current Liabilities | 654 K | |||
| Net Asset | 1.87 M |
About Biostage Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Biostage's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Biostage using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Biostage based on its fundamental data. In general, a quantitative approach, as applied to this otc stock, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Currently Active Assets on Macroaxis
Check out Trending Equities to better understand how to build diversified portfolios. Also, note that the market value of any otc stock could be closely tied with the direction of predictive economic indicators such as signals in estimate. You can also try the Options Analysis module to analyze and evaluate options and option chains as a potential hedge for your portfolios.
Other Consideration for investing in Biostage OTC Stock
If you are still planning to invest in Biostage check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Biostage's history and understand the potential risks before investing.
| My Watchlist Analysis Analyze my current watchlist and to refresh optimization strategy. Macroaxis watchlist is based on self-learning algorithm to remember stocks you like | |
| Bollinger Bands Use Bollinger Bands indicator to analyze target price for a given investing horizon | |
| Money Flow Index Determine momentum by analyzing Money Flow Index and other technical indicators |